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Background
In thalassemia intermedia (TI) patients no observational
study prospectively evaluated in the real life the efficacy
of the desferrioxamine (DFO) therapy in removing or
preventing myocardial iron overload. The efficacy end-
point of this study is represented by the changes in car-
diac T2* values and left ventricular (LV) function
parameters in non-transfusion dependent (NTD) TI
patients after 18 months of desferrioxamine therapy.
Methods
Among the 325 TI patients enrolled in the MIOT (Myo-
cardial Iron Overload in Thalassemia) network, we
selected 129 TI patients NTD. We considered 29
patients who had been received DFO alone between the
two MRI scans. Cardiac iron overload was assessed by
the multislice multiecho T2* technique. LV function
parameters were quantified by cine SSFP sequences.
Myocardial fibrosis was evaluated by late gadolinium
enhancement (LGE) acquisitions.
Results
Mean age was 39.69±8.12 years and 14 (48.3%) patients
were females. Patients started regular chelation therapy
at a mean age of 21.92±15.89 years. The mean adminis-
tered dosage of DFO via subcutaneous route was 38.46
±10.27 mg/kg body weight on 3.32±1.54 days/week. The
percentage of patients with excellent/good levels of
compliance to the chelation treatment was 82.1%.
At baseline only one patient showed cardiac iron over-
load (global heart T2*=15.23 ms) but he recovered at
the FU (global heart T2*=26.93 ms). All patients without
cardiac iron maintained the same status at the follow-up
(FU).
Due mainly to technical reasons, LV function was
assesses at both baseline and FU MRIs in 24 patients.
At baseline all patients had a normal LV ejection frac-
tion (EF) and 4 of them showed a reduced LV ejection
fraction (LVEF) at the FU. The changes between the
two MRIs in LV volumes and mass indexed by the body
surface area as well in EF were not significant.
No movement abnormalities were detected at the
baseline MRI while at the FU one patients showed ipo-
kinesia in basal and mid inferoseptal LV wall.
For 21 patients the presence of myocardial fibrosis was
investigated at both baseline and FU MRIs, and this sub-
group was considered. Three (14.3%) patients had myo-
cardial fibrosis at the baseline, all with a non ischemic
pattern.
At the FU two new occurrences of non-ischemic myo-
cardial fibrosis were detected.
Conclusions
In this small population of sporadically or non trans-
fused TI patients, the DFO therapy showed 100% effi-
cacy in maintaining a normal global heart T2* value but
it did not prevent the worsening of the LV function and
the occurrence of new myocardial fibrosis.
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